Mike Hennessy

Another ASCO annual meeting has come and gone, and now comes the fun part where we digest and interpret the significance of the mountains of new data presented.

In the oncology realm, specialty pharmacy has become a mainstay, but its role in urology practice is starting to trend upwards.

The road to becoming the first biosimilar to go on sale in the United States has been uneven for Zarxio (filgrastim-sndz), a Sandoz product for raising white blood cell counts.

As we embark on this inaugural issue of Contemporary Radiation Oncology, it occurs to me that the launch of every new journal is always made with the best intentions.

Immune checkpoint blockade strategies were a central focus of much of the key data presented at AACR.

During the past five years, the progress in therapeutic options for men with prostate cancer has been truly remarkable.

Competitive pressures and profound marketplace changes are a fact of life for the oncology business, and for a practice in San Antonio, Texas, that handles a large population of rural poor, planning sessions routinely involve discussions on how to stay independent and continue doing things the way physicians there feel is best.

Given the higher risk of breast and ovarian cancer in BRCA mutation carriers, should broader screening for the abnormality be implemented?

The rise of high-deductible health plans has been accelerated by the Affordable Care Act, yet for many oncology practices this trend adds to the administrative workload and creates deep uncertainty on the accounts receivable side.

It seems like the feature stories and meetings coverage this month singularly revolve around prostate cancer.

We are just completing the first quarter of 2015, and already there has been a series of exciting new treatment approvals offering new hope to patients with cancer.

The profound changes under way in the treatment of leukemia were among the highlights captured in our coverage of the 19th Annual International Congress on Hematologic Malignancies:® Focus on Leukemias, Lymphomas, and Myeloma.

The Giants of Cancer Care program recognizes those physicians and researchers who have devoted their time, talent, and resources to improving the care for the many patients and their families affected by cancer.

Research into anticancer vaccines is moving forward on several fronts.

There's widespread agreement on both sides of the aisle that Medicare's payment system needs to be replaced-that's a good start, considering the current emergency spending authorization, or ‘patch' is set to expire on March 31.

2015 has certainly got off to an exciting start in oncology!

The toolkit for attacking many tumor types is well stocked, and the prospects for continued progress are brighter than ever.

Oncology practices can ease their patients' financial concerns by connecting them to financial counseling services.

Leading researchers described several areas of significant advances during the 9th Annual New York Lung Cancer Symposium, a daylong conference that Physicians' Education Resource hosted November 8.

In a constantly changing and thus difficult-to-navigate healthcare world, thriving in community practice is nothing if not challenging.

Since the modern era of anticancer immunotherapy began about four years ago, a variety of strategies to awaken the patient's own defenses against tumor cells have been reported.

We explore the progress and challenges that circulating tumor cell technology offers toward that goal.

When it comes to biomarker-based cancer treatment, there are nearly endless avenues to explore.

Our coverage of the 15th Annual International Lung Cancer Congress, which Physicians' Education Resource (PER) hosted July 31-August 2 in California, illustrates how nuanced genomic targeting has become in NSCLC.

In our coverage of the 13th Annual International Congress on the Future of Breast Cancer, which Physicians' Education Resource hosted in California, we focus on aspects of clinical care that may be influenced by the ever-growing body of knowledge about the molecular nature of breast cancer.

Biomarkers. It's a term thrown around quite frequently in the cancer world.

The 2014 American Society of Clinical Oncology Annual Meeting provided ample evidence not only of the immunotherapy field's vitality but also of its breadth.

The world's largest gathering of urologists, the annual meeting of the American Urological Association, offered an array of information relevant to those who practice in the community setting.

We are pleased to present the second class of leading oncology specialists whom an esteemed advisory board has chosen to honor with our 2nd Annual Giants of Cancer Careâ„¢ awards.

When the mapping of the human genome was completed more than a decade ago, there was unbridled excitement about the impact that the wealth of new knowledge would have on medicine, particularly on cancer treatment.